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for their BP recordings. All routine and special investigations i.e.
flow mediated dilation (FMD), Ferric Reducing ability of plasma
(FRAP) & Malondialdehyde (MDA) were done in beginning as well
as at the end of 8 weeks.
Results: The reduction in mean SBP (-2.56mmHg), pulse pressure
(-1.88), total cholesterol (-18.10mg/dl) and triglyceride (-18.88mg/
dl) were significant (p<0.001) in rosuvastatin group but not in
placebo (p¼0.0722). Also, significant improvement in mean FMD
(+4.34%) and mean antioxidant (FRAP) was observed in rosuvas-
tatin group and however no such changes were seen in placebo
group (p¼0.73). There were no significant changes in diastolic
blood pressure and MDA levels in both rosuvastatin as well as
placebo group.
Conclusions: The addition of rosuvastatin in normocholester-
olemic subjects led to significant fall in mean systolic blood
pressure and mean pulse pressure with improvement of endo-
thelial function and antioxidant levels. Rosuvastatin can suppress
progression of atherosclerosis, decrease serum CRP production
and reduce cardiovascular events.This study reinforces relatively
poorly understood and under-reported hypotensive potential of
statin, one of many pleiotropic effect associated with the class of
statin.The reduction of systolic blood pressure and pulse pressure
have been strongly linked to reduced incidence of stroke in hy-
pertension and any intervention leading to reduction in these
parameters however small will go a long way in arresting the
crippling consequences.
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Background: Accelerated/Malignant hypertension (A/MH) is a
hypertensive emergency, clinically defined by the European so-
ciety of Hypertension/European society of cardiology (ESH/ESC) as
the presence of very high BP associated with target organ damage
(TOD) [retina, kidney, heart or brain]. The 5 years survival rate
reported after the diagnosis of A/MH has improved significantly
which could be due to earlier diagnosis, lower BP targets and
availability of new classes of antihypertensive agents.
Objective: To estimate the incidence of A/MH and evaluate its
prognosis and management.
Methods: A retrospective cohort analysis was carried out at our
2500 bedded tertiary care teaching hospital on patients admitted
with essential HTN (during 2008 - 2012) with ICD e 10 (I.10) coding
with no comorbidities with age40 were considered for the study.
Results: Of the 305 in-patients diagnosed with essential HTN, 17
(5.8%) were found to have Grade III HTN (ESH/ESC 2013) which
were documented as A/MH. Male predominance was found to be
higher with 53% with a mean age for 58 years (±10 SD) and mean
BMI of 23.8 (±4.7 SD). TOD identified in 17 patients were: 2 patients
(12%) ophthalmic, 9 (53%) left ventricular failure and none re-
ported in 6 (35%). All patients except one were treated with
amlodipine (88%) either as monotherapy or with other classes
including ARBs, ACEi, diuretics, beta blockers or clonidine. Read-
missions were reported in 5 (29%) with only 1(6%) being diagnosed
with CAD on the first readmission.
Conclusion: Going by the standard criteria for diagnosing A/MH
where BP is180/ 110, through our study we could safely conclude
that 14 patients (83%) were either not reported with visual
changes or not being referred for ophthalmic evaluation. This
could also
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Background: Nocturnal hypertension is a common complication
of essential and secondary hypertension. Abnormal elevated
sleep blood pressure [nocturnal nondipper] is associated with
increased target-organ damage and adverse cardiovascular
outcomes.
Methods: Prospective cohort observational study. All known hy-
pertensive patients of any age and sex enrolled in the medical
clinics of central hospital,S.E.C.Railway, Bilaspur [C.G.] are stud-
ied. Period of study was from Apr’ 2012 to June’2014 [26 months].
Inclusion criteria - Hypertension as per JNC VII guideline are
selected from both sexes. History of taking more than three
antihypertensive drugs including one diuretics.
Ambulatory Blood Pressure Monitoring [ABPM] is done by two
equipments of model AMBULO 2400 [Mortara] with special soft
ware. Non-Dipper is identified by the software if there is <10%
drop of blood pressure during sleep hours. Morning 6 am to night
10 pm is awake period during which blood pressure is recorded
every 30 minutes and during sleep hours 10 pm to 6 am] it
recorded hourly. Microalbuminuria is done by urine MICRAL test.
Standard lab technique is used for Serum Uric acid and Homo-
cysteinemia. Left Ventricular Hypertrophy is recorded by 2-D color
echocardiography.
Results: Total no of patients enrolled were 212 [female¼46, Ages
ranged from 27 year to 80 years, [ average age was 49 +/- 13] non-
dippers were¼22[9.6%].Healthy controls were 72 [female¼14] ,
non-dippers were 3[0.04%]. Micralbuminuria in Dippers, non-
dippers and controls were 18,12 and 0 [p¼<0.0001] respectively.
High serum uric acid were in 24, 8 and 0 in dipper, non-dipper and
controls respectively [p¼<0.0001], High serum homocystein were
in 12,8 and 6 in dipper, non-dipper and controls respectively
[p¼<0.0001]. Left Ventricular Hypertrophy [LVH] were seen in 36,









Microalbuminuria 018(9%) 12 (54%) 0 ( 0%) <0.0001
High Uric acid 24 (12%) 08(36%) 0 (0%) <0.0001
LVH 36 (18%) 18 (81%) 2 (2.7%) <0.0001
High
homocystein
12 (6%) 08(36%) 06(8%) <0.0001
Conclusions: Non-dippers evaluated by the ABPM system can be
used as a clinical surrogate marker for oxidative stress and target
organ damage in chronic hypertension and hence this simple tool
can help the physician to implicate for appropriate therapeutic
plans.
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